Literature DB >> 32418755

Treatment outcomes of patients with tracheobronchial mucoepidermoid carcinoma compared with those with adenoid cystic carcinoma.

Yalong Wang1, Songhua Cai2, Qi Xue1, Juwei Mu2, Yushun Gao1, Fengwei Tan1, Yousheng Mao1, Dali Wang1, Jun Zhao1, Shugeng Gao3, Jie He4.   

Abstract

OBJECTIVE: Tracheobronchial mucoepidermoid carcinoma (TMEC) is an extremely rare salivary gland-type neoplasm. We aimed to explore the clinical characteristics and prognosis of TMEC and to compare them with those of another rare salivary gland-type neoplasm, tracheobronchial adenoid cystic carcinoma (TACC).
METHOD: We performed a retrospective review of all patients pathologically diagnosed with TMEC between 1965 and 2017 at our institution. We reviewed the patients' clinical characteristics, treatment methods and outcomes and compared the results of TMEC and TACC patients.
RESULTS: A total of 115 consecutive patients, including 107 who underwent surgery and 8 who received nonoperative therapy, were included in our study. The 1-, 2-, and 5-year survival rates were 97.89%, 94.17%, and 90.50%, respectively, in the surgical group and 83.33%, 41.67% and 0.00%, respectively, in the nonoperative group. The multivariate analysis showed that N stage was an independent prognostic factor for overall survival (OS). TMEC patients were younger, had a shorter complaint duration, had fewer symptoms, had more bronchial tumors, and were more likely to undergo surgical treatment and achieve an R0 resection (surgically treated patients) than TACC patients; furthermore, TMEC patients had a significantly better OS than TACC patients (P < 0.050).
CONCLUSIONS: TMEC has different characteristics and a better prognosis than TACC, which may reflect the different biological behaviors of these two salivary gland neoplasms. Radical treatment and close follow-up are critical for surgically treated TMEC patients with lymph node metastasis.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Carcinoma; Mucoepidermoid; Trachea; Treatment outcome

Mesh:

Substances:

Year:  2020        PMID: 32418755     DOI: 10.1016/j.ejso.2020.04.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China.

Authors:  Jiagen Li; Fengwei Tan; Yalong Wang; Qi Xue; Yushun Gao; Juwei Mu; Yousheng Mao; Jun Zhao; Dali Wang; Xiaoli Feng; Susheng Shi; Kenichi Suda; Giuseppe Cardillo; Luca Bertolaccini; Maurizio V Infante; Paul E Van Schil; Shugeng Gao; Jie He
Journal:  Transl Lung Cancer Res       Date:  2022-05

2.  Surgical treatment of primary tracheobronchial tumors: 16-year experience in a single center.

Authors:  Yujian Liu; Kaifu Zheng; Qiang Lu; Jian Wang; Yunfeng Ni; Xiaolong Yan; Lei Wang; Xiyang Tang; Jing Huang; Xiaofei Li; Jinbo Zhao
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

3.  The Clinical and Prognostic Characteristics of Primary Salivary Gland-Type Carcinoma in the Lung: A Population-Based Study.

Authors:  Lei-Lei Wu; Jia-Yi Qian; Chong-Wu Li; Yu Zhang; Wei-Kang Lin; Kun Li; Zhi-Xin Li; Dong Xie
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

4.  Case Report: Uniportal Video-Assisted Thoracoscopic Parenchymal Sparing Secondary Carinal Resection and Reconstruction for the Treatment of Tracheobronchial Mucoepidermoid Carcinoma.

Authors:  Yan Hu; Xiaofeng Chen; Siying Ren; Chao Zeng; Li Wang; Peng Xiao; Fenglei Yu; Wenliang Liu
Journal:  Front Surg       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.